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Abstract
Women’s metabolism during pregnancy undergoes numerous changes that can lead to gestational diabetes mellitus (GDM). The cause and patho-
genesis of GDM, a heterogeneous disease, are not completely clear, but GDM is increasing in prevalence and is associated with the modern lifestyle. 
Most diagnoses of GDM are made via the guidelines from the International Association of Diabetes and Pregnancy Study Groups (IADSPG), which 
involve an oral glucose tolerance test (OGTT) between 24 and 28 weeks of pregnancy. Diagnosis in this stage of pregnancy can lead to short- and 
long-term implications for the mother and child. Therefore, there is an urgent need for earlier GDM markers in order to enable prevention and earlier 
treatment. Routine GDM biomarkers (plasma glucose, insulin, C-peptide, homeostatic model assessment of insulin resistance, and sex hormone-bin-
ding globulin) can differentiate between healthy pregnant women and those with GDM but are not suitable for early GDM diagnosis. In this article, 
we present an overview of the potential early biomarkers for GDM that have been investigated recently. We also present our view of future deve-
lopments in the laboratory diagnosis of GDM.
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Introduction
During pregnancy, women’s metabolism under-
goes numerous changes with respect to carbohy-
drates, fats and proteins in order to provide the 
nutrients and oxygen needed for foetal growth, 
and to fill the extra energy stores required for de-
livery and lactation (1). Major changes in any of 
these metabolic pathways can lead to gestational 
diabetes mellitus (GDM). Gestational diabetes mel-
litus is an independent type of diabetes defined as 
glucose intolerance, with first recognition arising 
during pregnancy (mostly in the second trimester 
between the 24th and 28th week of gestation) and 
resolving after pregnancy.
Today 1-36% of pregnant woman suffer from GDM, 
depending on the population and criteria used. 
The incidence of GDM increases along with in-
creases in the prevalence of obesity and diabetes 
mellitus type 2 (T2DM), which are most commonly 
associated with the modern lifestyle (2,3). 
The cause and pathogenesis of GDM, a heteroge-
neous disease, are not completely clear; they could 
relate to genetic alteration, the deregulation of 
placental hormones, or ß-cell injury (similar to 
type 1 diabetes) (4). Pregnancy is a state involving 
metabolic changes, in which the mothers’ physio-
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logical systems adjust to enable normal foetal de-
velopment. In a healthy pregnancy, insulin insensi-
tivity caused by maternal and placental hormones 
(prolactin, estrogen and cortisol) gradually devel-
ops, with a reciprocal increase in insulin secretion 
of 200% to maintain euglycaemia, and insulin sen-
sitivity decreases by as much as 70% (5-7). Gesta-
tional diabetes mellitus is a pathophysiological 
state in which there is insufficient insulin available 
to maintain glucose concentrations in normal 
range, and hyperglycaemia occurs. Glucose con-
trol in pregnancy depends on ß-cell insulin secre-
tion, the insulin clearance required to maintain the 
balance of hormonal changes in pregnancy, and 
insulin actions in the liver, muscles and tissues. Dis-
ruption in any of these factors leads to insulin re-
sistance during pregnancy and increased serum 
glucose (8,9).
In addition, pregnancy is a proinflammatory con-
dition, and the immune response of the maternal 
immune system during pregnancy is not well reg-
ulated under GDM conditions. A common symp-
tom of hyperglycaemic conditions, including 
GDM, is oxidative stress, which induces an inflam-
matory response and increases insulin resistance. 
Oxidative stress also affects the proliferation, acti-
vation, cytokine secretion and damage of cellular 
components (10,11). Inflammatory cytokines and 
insulin post-receptors interact to block the normal 
tyrosine phosphorylation of the insulin receptor 
substrate, reducing its ability to bind the insulin re-
ceptor and thus affecting the regulation of glu-
cose metabolism (12). Pathophysiological events 
specific to GDM are presented in Figure 1.
Gestational diabetes mellitus complications in-
volve intrauterine metabolic alterations in infants, 
and impact foetal programing, with long-term 
consequences later in life (13). Gestational diabe-
tes mellitus has short- and long-term implications 
for the mother as well. For the mother, the short-
term consequences include hypertensive disor-
ders in pregnancy, failures in progress in labour, 
the requirement of caesarean section, pre-term 
delivery, and preeclampsia. The long-term impli-
cations are associated with recurrent GDM in sub-
sequent pregnancies, T2DM, and cardiovascular 
diseases later in life. The short-term implications 
for the child include macrosomia, perinatal death, 
neonatal hypoglycaemia, shoulder dystocia and 
related birth injures, hyperbilirubinemia, and a low 
Apgar score (2,14). The long-term implications for 
the child are T2DM, obesity, and GDM (females 
only) (7). As such, it is important to find early bio-
markers that will help to predict GDM and initiate 
Figure 1. Pathophysiological events specific to gestational diabetes mellitus (GDM). IRS-1 - Insulin receptor substrate 1. ROS - reactive 
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the appropriate treatment to prevent complica-
tions. The main challenge is to find a good bio-
marker for early diagnosis of GDM, which requires 
having a truly representative sample, and the de-
termination of the exact cut-off point to distin-
guish healthy pregnant women from those with 
GDM. Any method that is inexpensive, readily 
available, automated, and provides results quickly 
would be welcomed, as would the derivation of 
biomarkers via minimally invasive methods. 
Methods
With the aim to provide an overview of the early 
biomarkers of GDM that have recently been pub-
lished, we have searched PubMed, Ovid MEDLINE 
and Web of science databases between January 
and March 2021. Keywords used were: gestational 
diabetes, biomarkers, GDM risk, inflammation, 
GDM amino acid biomarker, amino acid profiles in 
GDM and metabolism or immunology. Articles, re-
gardless of the time frame, in which analysed sam-
ple was blood or urine were included, while arti-
cles that discuss treatment of GDM were excluded 
from this review. The articles included are original 
articles with the results of clinical studies or review 
articles. In addition to articles found in the data-
bases, the guidelines from national societies used 
in routine GDM diagnostics were used to write this 
review. 
Diagnosis of GDM
Most diagnoses of GDM are made according to the 
guidelines from the International Association of 
Diabetes and Pregnancy Study Groups (IADSPG), 
which involve performing an oral glucose toler-
ance test (OGTT) between 24 and 28 weeks of 
pregnancy. In 2010, the Hyperglycemia and Ad-
verse Pregnancy Outcome (HAPO) study estab-
lished new thresholds for OGTT determination be-
tween 24 and 28 weeks of pregnancy: 5.1 mmol/L 
for fasting plasma glucose, 10 mmol/L for one-
hour plasma glucose and 8.5 mmol/L for two-hour 
plasma glucose. The World Health Organization 
(WHO) has accepted these thresholds, and these 
guidelines have also been accepted by the Croa-
tian Society for Gynecology and Obstetrics and 
the Croatian Chamber of Medical Biochemists (15-
17). The National Institute of Health (NIH) suggests 
a two-step diagnostic test between the 24th and 
28th weeks of gestation: a 1-hour screening test 
with 50 g of glucose for all pregnant women, and 
then a 100 g OGTT for women who meet or ex-
ceed the screening threshold for a blood glucose 
concentration of 7.2, 7.5 or 7.8 mmol/L in the first 
step (18,19).
An alternative test uses glycated haemoglobin 
(HbA1c), which has less interlaboratory variation, 
less intraindividual variability, and is not affected 
by meals, fasting, acute stress or medications (6). 
However, no thresholds have been established for 
HbA1c in pregnancy; in four studies, different 
thresholds (5.0, 5.3, 5.5 and 7.5%, respectively) 
were estimated for GDM (20-23). However, most 
guidelines recommend HbA1c > 6.5% for the diag-
nosis of GDM (24).
Existing international guidelines recommend test-
ing for pregestational diabetes in women in early 
pregnancy with body mass index (BMI) > 30 kg/
m2, impaired glucose tolerance, and a history of 
GDM (7).
Conventional predictive GDM 
biomarkers
Fahami et al. and Riskin-Mashiah et al. showed that 
fasting glucose concentrations above 5 mmol/L in 
early pregnancy were useful for the prediction of 
GDM (25,26), while Donovan et al. reported fasting 
glucose concentrations over 4.7 mmol/L as a 
threshold for GDM (27). Li et al. recently reported 
results of their study which included 2112 preg-
nant women and concluded that a fasting glucose 
concentration over 4.5 mmol/L during the first tri-
mester offers optimal specificity and sensitivity for 
GDM prediction (28). The fasting plasma glucose 
concentration was more accurate than other tradi-
tional risk factors, such BMI or age,  when used for 
GDM prediction, but it was less accurate than 
OGTT testing (25,26,29).
There is evidence to suggest that insulin and C-
peptide values are good predictors of GDM. Both 
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insulin measurements-fasting insulin and OGTT in-
sulin (or two-hours-postprandial insulin) showed 
good sensitivity and specificity (30,31). The con-
centrations of fasting insulin and C-peptide are 
significantly higher in pregnant women with GDM 
than in healthy pregnant women. 
Homeostatic model assessment for insulin resist-
ance (HOMA-IR) is calculated from the values of 
fasting glucose and fasting insulin or C-peptide. 
The homeostatic model assessment for insulin re-
sistance has mostly been reported to be signifi-
cantly more abundant in pregnant women with 
GDM, and is a good predictor of GDM (7). Howev-
er, some studies have downplayed the significance 
of HOMA-IR compared to other parameter, or sug-
gested there is no difference between pregnant 
women with GDM and healthy pregnant women 
(14,32). Therefore, it can be concluded that the sig-
nificance of HOMA-IR is questionable, and HOMA-
IR alone is insufficient for use as a predictive mark-
er for GDM.
Sex hormone-binding protein (SHBG) is a glyco-
protein produced by the liver. Its production and 
plasma concentrations are controlled by insulin, 
estrogen, and progestin. Sex hormone-binding 
protein has an inverse relationship with insulin re-
sistance, and has therefore been proposed as a 
predictive marker for GDM. The synthesis of SHBG 
is stimulated by estradiol, meaning high estrogen 
concentrations during pregnancy increase SHBG 
concentrations (33,34). Testosterone reduces the 
synthesis of SHBG, and low concentrations of 
SHBG with high concentrations of testosterone are 
linked with T2DM. Lower SHBG values before 
pregnancy and in early pregnancy have been 
linked with an increased risk of GDM (5).
Methods for determining SHBG, C peptide or insu-
lin are immunochemical, which are subject to nu-
merous interferences and reference intervals differ 
depending on analyser and the reagent used. In 
order to be able to determine the right cut off val-
ue, the large enough sample of the pregnant pop-
ulation is needed for each method. This is difficult 
and almost impossible to establish because preg-
nant women are sensitive population, so we be-
lieve that markers determined by immunochemi-
cal methods are not the best choice for early GDM 
diagnosis. 
Leptin is a hormone produced by the adipocytes, 
ovaries, and placenta. It regulates energy intake 
and expenditure, and its levels are increased in 
obesity. As a result of placental production during 
pregnancy, leptin concentrations are higher in 
pregnant than in non-pregnant women (2). In 
GDM, a more significant increase in leptin concen-
trations is seen, although these data are ambigu-
ous due to the production of leptin in the ovaries 
and placenta as well.
Adiponectin is a protein produced by adipocytes 
and has anti-inflammatory and antiatherogenic 
properties, regulating glucose and fatty acid me-
tabolism (6). Unlike leptin, it is not produced by 
the ovaries and placenta, and does not cross to 
foetal circulation (35). Reduced adiponectin con-
centrations are associated with obesity, hyperten-
sion and T2DM. In pregnancy, the concentrations 
of adiponectin are reduced most likely as a re-
sponse to reduced insulin sensitivity (2). Previous 
studies have reported that adiponectin concentra-
tions in the first and second trimesters of pregnan-
cy are lower among women who develop GDM in 
their third trimester (5).
Leptin and adiponectin are most often deter-
mined by enzyme-linked immunosorbent assays 
(ELISA), which means that there are limitations and 
interferences as in other immunochemical meth-
ods. Enzyme-linked immunosorbent assays are of-
ten not fully automated and therefore material 
loss is possible. The advantage of using ELISA in 
measuring those biomarkers is that the determina-
tion of these parameters does not require preg-
nant women to be fasting.   
Amino acid and fatty acids profiling
Metabolomics studies have shown that branched 
amino acids (BCAAs) and aromatic amino acids are 
associated with T2DM and GDM. BCAAs are in-
volved in several metabolic pathways of insulin re-
sistance, and studies have shown that BCAAs re-
duce insulin secretion through their effects on 
pancreatic β-cells (36). The BCAAs valine, leucine 
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and isoleucine are the most hydrophobic amino 
acids, and have been linked to obesity, insulin re-
sistance and T2DM. Additionally, several clinical 
studies using liquid chromatography-mass spec-
trometry (LC-MS) and targeted nuclear magnetic 
resonance (NMR) approach have shown these ami-
no acids present at higher concentrations in preg-
nant women with GDM compared to healthy preg-
nant women, and they increase in the first trimes-
ter, so they can be counted as predictive biomark-
ers of GDM (37,38). Using a combination of an NMR 
metabolome and conventional laboratory assays, 
White et al. reported that concentrations of the 
BCAAs valine, leucine and isoleucine were higher 
in the second and the third trimesters of pregnan-
cy in women with GDM compared to healthy preg-
nant women; unlike the aromatic amino acids phe-
nylalanine and tyrosine, which were elevated only 
in the third trimester in women with GDM com-
pared to the control group (39). Other studies also 
showed that elevated phenylalanine concentra-
tions increase the risk of GDM (37,38).  
The sulfur-containing amino acids include methio-
nine, cysteine, cystine and homocysteine. They 
play a role in cellular systems and are associated 
with vascular disease and cancer. Their concentra-
tions, determined by high-performance liquid 
chromatography (HPLC) and HPLC-MS/MS, differ in 
pregnant women with GDM compared to healthy 
pregnant women; cysteine concentrations are 
higher in GDM, whereas methionine concentra-
tions are lower, and the results for homocysteine 
concentrations are conflicting (18,40,41).
In Nevalainen et al.’s study, in the first trimester of 
pregnancy, only the arginine concentrations were 
higher, while the glycine concentrations were low-
er in GDM pregnant women compared to the con-
trol group analysed by micro mass spectrometry 
(42). Rahimi et al. reported that in women with 
GDM, arginine, glycine and methionine measured 
by HPLC were present at higher concentrations, 
and rises in asparagine, threonine, aspartate, phe-
nylalanine, glutamine and arginine increased the 
risk of GDM (43).
Several studies have reported changes in seroto-
nin metabolism in GDM, considering that seroto-
nin is a metabolite of tryptophan, and both play a 
role in regulating foetal growth and development. 
There are differences in serotonin concentrations 
analysed by stable isotope dilution direct-infusion 
method (SID-MS) and ultra-performance liquid 
chromatography/hybrid quadrupole time-of-flight 
mass spectrometry (UPLC-TOF-MS) assays be-
tween GDM pregnant women and healthy preg-
nant women; more precisely, serotonin concentra-
tions are higher in GDM (44,45).
The literature overview demonstrates that the re-
sults from previously published amino acid experi-
ments are contradictory, most likely due to differ-
ences in the trimesters of pregnancy at which the 
research was conducted, the BMI and other co-
morbidities of the study groups, and the definition 
of GDM. 
Fatty acid and lipid metabolism are intrinsic to the 
supply of energy needed for the foetus to grow 
and develop, and to the structural components of 
cells. Previous studies have suggested there are 
not many benefits in measuring the routine bio-
chemical parameters of lipid status; increased tri-
glyceride concentrations and lower high-density 
lipoprotein cholesterol in GDM have been demon-
strated, but given their low specificity, these can-
not be considered as markers of GDM (7,35).
In normal pregnancy, the concentrations of foetal 
fatty acids depend on the maternal concentra-
tions. The proportion of saturated fatty acids 
(SFAs) increases as the pregnancy progresses, and 
the foetal concentrations of long-chain polyunsat-
urated fatty acids (LCPUFAs) depend on maternal 
intake (46). The essential fatty acids omega-3 and 
omega-6 are precursors of a number of regulatory 
molecules. Several studies have shown that the 
placental uptake of LCPUFAs and essential fatty 
acids were reduced in GDM compared to healthy 
pregnancies, and that the transfer of SFAs was un-
affected (47).
Free fatty acids (FFA) could also be responsible for 
the reduced capacity of pancreatic ß-cells and the 
elevated insulin resistance in GDM. In 1996, Meyer 
et al. showed that women with GDM had FFA con-
centration that were more than double those 
found in healthy pregnant women (48).
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One study showed that insulin GDM treatment 
might activate placental insulin receptors protein 
kinase and mediators of extracellular signal-regu-
lated kinase, leading to an increased expression of 
fatty acid carriers in the placenta and the adiposity 
of the foetus. Other studies showed that omega-3 
fatty acid supplementation contributes to a better 
outcome in GDM, a low incidence of hyperbiliru-
binemia, and a reduced hospital rate in new-borns. 
Furthermore, the results were even better if vita-
min E supplements were taken (47). 
Analytical methods for measuring amino acids 
and fatty acids are GC-MS and LC-MS which are de-
manding and not always available in clinical labo-
ratories. This methods are time consuming and re-
quire additional pre-analytical steps which may re-
sult in material loss, which are the reasons they did 
not become routine practice. 
Inflammatory biomarkers 
As the inflammatory response is enhanced in 
GDM, inflammatory markers are probably involved 
in the development of GDM and could be used as 
predictive markers. Indeed, numerous studies 
have shown that inflammatory markers could pre-
dict GDM as early as the first trimester of pregnan-
cy (49).
The C-reactive protein (CRP) and the highly sensi-
tive C-reactive protein (hs-CRP) are inflammatory 
markers, and are elevated in pregnancy. Further-
more, pregnant women with GDM show even high-
er concentrations compared to healthy pregnant 
women (2,5,7). Since different studies used different 
methods to assess CRP and different criteria to diag-
nose GDM, some failed to report elevated CRP in 
women with GDM (50). Furthermore, when BMI is 
adjusted, the relationship between CRP and GDM 
becomes weaker or disappears (51). Due to the 
above-mentioned contradictory findings and CRP’s 
low specificity, it is unlikely to be useful as an inde-
pendent and specific marker for GDM.
Tumour necrosis factor alpha (TNF-α) and interleu-
kin-6 (IL-6) are the main inflammatory cytokines 
increased in insulin resistance and GDM. Given 
their suppression of insulin signal pathways and 
interference with the anti-inflammatory effects of 
insulin, they are potential mediators of insulin re-
sistance. Insulin reduces the concentrations of re-
active oxygen species produced by mononuclear 
cells, but this is inhibited by the above-mentioned 
cytokines (2,9,52,53). Both are derived from the 
placental and maternal immune systems, which 
are mutually tuned to protect the foetus in the 
maternal organism. In GDM, the maternal profile 
remains proinflammatory, and the TNF-α and IL-6 
concentrations remain elevated (49,54). TNF-α and 
IL-6 are involved in the disruption of insulin signal-
ling and the further stimulation of gene expres-
sion related to insulin resistance (55). TNF-α acts by 
inhibiting the tyrosine phosphorylation of the in-
sulin receptor, and thus suppresses insulin signal 
transduction. IL-6, up to 30% of which is produced 
by adipose tissue (56,57), negatively regulates in-
sulin signalling and glucose metabolism in adipo-
cytes, and promotes insulin resistance in liver cells 
(47). A great number of studies have found a posi-
tive association between elevated TNF-α and IL-6 
in women with GDM. However, other studies have 
failed to find such significant relationships (7,58). 
Since heterogeneity in concentrations of TNF-α 
and IL-6 was found at different stages of normal 
pregnancy, it is necessary to further characterize 
their concentrations at certain time points during 
pregnancy, which would make TNF-α and IL-6 rel-
evant markers for GDM. What favours the above 
mentioned markers is that they are determined by 
automated biochemical (CRP) and immunochemi-
cal methods (TNF-α and IL-6) in serum and are ap-
plicable to most biochemical and immunochemi-
cal analysers due to increasing clinical application 
in other conditions and could easily be routinely 
measured for the diagnosis of GDM if future re-
search confirms their clinical value. 
Whole blood parameters 
Since inflammatory parameters may indicate an 
increased risk of developing GDM, numerous stud-
ies have tried to find a suitable marker in whole 
blood. 
Erythrocytes have surface-complement receptors, 
and remove immune complexes from circulation 
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in autoimmune diseases and infections. Yang et al. 
reported that women with GDM had significantly 
higher values of erythrocytes, and lower mean 
corpuscular volume and mean corpuscular hae-
moglobin values (59).
Leukocyte number is a biomarker of systemic in-
flammation. Many studies have reported that 
women with GDM had significantly higher counts 
of leukocytes, neutrophils, lymphocytes and 
monocytes (11,59). Furthermore, most clinical 
studies reported that the ratio of these cells is a 
suitable GDM marker - for example, an elevated 
neutrophil/lymphocyte ratio (NLR) and monocyte/
lymphocyte ratio (MLR) (11,60-62).
Activated platelets release chemokines and P-se-
lectin, and express a variety of membrane recep-
tors involved in inflammation. Yang et al. reported 
that women with GDM displayed significantly 
higher values of platelets and lower mean platelet 
volume (MPV) values (59). On the contrary, in their 
clinical studies Kebapcilar et al. and Liu et al., wom-
en with GDM had higher MPV values associated 
with platelet aggregation, increased thromboxane 
A2 and ß-thrombomodulin release, and increased 
expressions of the receptors of adhesion mole-
cules, which could cause venous occlusion and va-
soconstriction (8).
However, although blood count is the most availa-
ble and affordable measurement and the values 
obtained are comparable among the different 
manufacturers, these parameters are not of high 
value since whole blood parameters are nonspe-
cific (both in individuals and ratios) and are found 
to be altered under various inflammatory condi-
tions. Certain parameters obtained via the newer 
technologies that are in routine application today, 
such as flow cytometry, have a higher value.
The immune system is composed of the innate im-
mune system and the adaptive immune system, 
and T lymphocytes are major components of the 
immune response. The balance between proin-
flammatory and anti-inflammatory cells is very im-
portant for maintaining the homeostasis of the 
immune system, and for preventing inflammatory 
diseases. The T helpers Th1 and Th17 are proin-
flammatory cells, while regulatory T-cells (Treg) 
and Th2 are anti-inflammatory cells. In GDM, the 
ratio of proinflammatory to anti-inflammatory 
cells changes with increases in Th1 and Th17 cells 
and reductions in Th2 and Treg cells (63). Th1 cells 
play a pathogenic role by activating macrophages 
and cytotoxic T-cells, and secrete some interleu-
kins such as IL-2 and interferon gamma (IFN-γ), 
while Th2 cells induce the production of interleu-
kins (IL-4 and IL-10) that play a protective role dur-
ing GDM. Th2 cells are also involved in allergic re-
sponses by activating the IgE antibody-producing 
ß-cells (52,64). Several clinical studies on a small 
number of respondents have attempted to deter-
mine the lymphocyte subpopulations in GDM 
with flow cytometry, because different cell sub-
populations exhibit different clusters of differenti-
ation (CD) molecules. The conclusions of these 
studies are that in GDM, the concentrations of T-
cells (CD3+), T-helper cells (CD3+, CD4+) and cyto-
toxic T-cells (CD3+, CD8+) are elevated compared 
to healthy controls (65-67).
Novel GDM biomarkers
One routine laboratory test that has shown lower 
values in GDM compared to a healthy control 
group is that which assesses brain natriuretic pep-
tide (BNP) (5). Some new biomarkers have also aris-
en with the potential ability to predict GDM. The 
old and new GDM biomarkers are presented in Ta-
ble 1.
Afamin is a vitamin E-binding protein found in hu-
man plasma, which plays a role in the antiapoptot-
ic cellular processes associated with oxidative 
stress. Afamin concentrations are associated with 
the presence of insulin resistance among patients 
with polycystic ovary syndrome and it is deter-
mined by ELISA method. Koninger et al. in their 
study, which included 59 women with GDM and 
51 healthy pregnant women, showed that women 
with GDM requiring insulin showed higher afamin 
serum concentrations than diet-treated patients in 
first trimester (68). 
Fibroblast growth factor 21 (FGF21) is a metabolic 
hormone produced by the adipose tissue, liver, skel-
etal muscle and pancreas, and it is reported that its 
serum concentrations are higher under conditions 
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Pregnancy period Values in GDM pregnancy References
Conventional predictors
Impaired glucose tolerance Between weeks 24 and 28 Assessed by OGTT: fasting > 5.1 mmol/L, 1
st hour > 
10 mmol/L or 2nd hour > 8.5 mmol/L 15-17
Glycated haemoglobin NA > 6.5% (48 mmol/mol) 24
Body mass index NA > 30 kg/m2 7
History of GDM NA positive 7
Conventional GDM biomarkers
Fasting plasma glucose Early pregnancy > 5 mmol/L, > 4.7 mmol/L or > 4.5 mmol/L 23,25-27
Hormones involved in energy homeostasis
C-peptide NA ↑ C-peptide 30,31
Fasting insulin NA ↑ insulin 30,31
Impaired insulin sensitivity NA
Deviation from normal insulin concentrations 
assessed by measurement of fasting insulin and 
OGTT insulin (or 2 h postprandial insulin)
28
Homeostatic Model Assessment of 
Insulin Resistance NA Insufficient as a predictive marker for GDM 7
SHBG Before and in early pregnancy ↓ SHBG 5
Leptin
During the whole 
pregnancy (because of 
placental production)
↑ leptin 2
Adiponectin In the first and second trimester
↓ adiponectin among women who develop GDM 
in the third trimester 2,5
Amino acid profile
Branched amino acids 
In the first trimester; 
also valine, leucine and 
isoleucine in the second 
and third trimesters
↑ valine, ↑ leucine and ↑ isoleucine 36-38
Aromatic amino acids In the third trimester ↑ phenylalanine and ↑ tyrosine 98
Sulfur-containing amino acids NA ↑ methionine, contradictory findings for cystine and homocysteine 18,40,41
Arginine In the first trimester ↑ arginine 42
Glycine In the first trimester Contradictory findings 42
Other amino acids NA
When ↑ asparagine, ↑ threonine, ↑ aspartate, 
↑ phenylalanine, ↑ glutamine  
risk of GDM is increased
43
Tryptophan metabolite, serotonin NA ↑ serotonin 44,45
Fatty acids
Long chain polyunsaturated fatty 
acids and essential fatty acids NA ↓ placental uptake 46
FFA NA ↑ FFA 47
Inflammatory biomarkers
C-reactive protein (CRP) or highly 
sensitive C-reactive protein 
(hs-CRP) 
NA ↑ CRP, ↑ hs-CRP; not specific to pregnancy 2,5,7
Table 1. Gestational diabetes mellitus predictors and biomarkers 
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Pregnancy period Values in GDM pregnancy References
Tumour necrosis factor alpha NA Contradictory findings 53,57,58
Interleukin-6  NA Contradictory findings 53,57,58
Whole blood parameters (not specific for pregnancy)
Blood cell count (erythrocytes, 
leukocytes, neutrophils, 
lymphocytes and monocytes)
NA ↑ blood cell count 12,59
MCV and MCH NA ↓ MCV and MCH 59
Ratio of blood cells (e.g., NLR or 
MLR) NA ↑ NLR, ↑ MLR 11,60-62
Platelet count NA ↑ platelet count 59
MPV NA ↓ MPV 59
Ratio of pro-inflammatory 
T-helpers (Th1 and Th17) and 
anti-inflammatory cells (T 
regulatory cells, Treg, and Th2)
NA ↑ ratio Th1 and Th17 to Treg and Th2 63
CD3+, CD4+, CD8+ NA ↑ CD3+, CD4+, CD8+ 65,66,67
Novel GDM biomarkers
BNP NA ↓ BNP 5
Afamin First trimester ↑ afamin 68
FGF21 First trimester ↑ FGF21 69
ANGPTL8 Early pregnancy ↑ ANGPTL8 70
Placental lactogen NA ↑ placental lactogen 71
Galanin Second trimester ↑ galanin 72
VAP1 Second trimester ↑ VAP1 73
FABP4 Second trimester ↑ FABP4 74
Fetuin-A or AHSG In the first and second trimester ↑ fetuin-A 78-82
pGCD59 Prior week 20 ↑ pGCD59 95
Extracellular vesicles  Between weeks 11 and 14 Characteristic content, further research necessary 75,77
Maternal microbiota NA Contradictory findings, better used as monitoring tool 85-92
PIGF Early pregnancy ↑ PIGF 96,97
GDM - gestational diabetes mellitus. NA - not applicable. OGTT - oral glucose tolerance test. SHBG - sex hormone-binding protein. 
FFA - free fatty acids. CRP - C-reactive protein. hs-CRP - high sensitive C-reactive protein. MCV - mean corpuscular volume. MCH 
-mean corpuscular haemoglobin. NLR - neutrophil to lymphocyte ratio. MLR - monocyte to lymphocyte ratio. MPV - mean platelet 
volume. Th - inflammatory T-helpers. CD - cluster of differentiation. BNP - brain natriuretic peptide. FGF21 - fibroblast growth 
factor 21. ANGPTL8 - angiopoietin-like protein 8. VAP1 - vascular adhesion protein 1. FABP4 - fatty acid-binding protein 4. AHSG - 
α2-Heremans-Schmid glycoprotein. pGCD59 - plasma glycated CD59. PIGF - placenta growth factor.
of insulin resistance and obesity. FGF21 is measured 
using ELISA. Zibar et al. found that in nine healthy 
people, the postprandial insulin concentration cor-
related with basal FGF2, and Bonakdaran et al. 
found no difference in insulin resistance between 
healthy pregnant women and pregnant women 
with GDM, but women with GDM showed higher 
concentrations of FGF21 in first trimester (32,69). 
Their study included 30 pregnant women with 
GDM and 60 healthy ones, so we believe that more 
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pregnant women are needed to examine true value 
of FGF21 as a biomarker of GDM.
Angiopoietin-like protein 8 is involved in lipid and 
glucose homeostasis, and its concentrations were 
found to be higher under conditions of GDM than 
normal pregnancy. Huang et al. showed  in their 
study on 474 pregnant women that its determina-
tion by ELISA method in early pregnancy could be 
important as an early biomarker of GDM (70). 
Placental lactogen is a peptide hormone secreted 
by endocrine cells, it plays a role in the regulation 
of insulin secretion and can be determined by ELI-
SA methods. Recently published review shows 
that increased concentrations of placental lacto-
gen are found in GDM, and that placental lactogen 
is also one of the biomarkers with potential appli-
cability in predicting GDM (71).
Galanin is a neuropeptide that reduces insulin re-
sistance and improves glucose uptake. In a study 
by Dincgez Cakmak et al., values of galanin in sec-
ond trimester were higher in 30 blood samples 
from GDM pregnant women when compared to 
30 healthy pregnant women (72). Vascular adhe-
sion protein 1 (VAP-1) is a glycoprotein that plays a 
role in inflammation and oxidative stress, whose 
blood values, according to Dincgez Camak et al.’s 
clinical study, are elevated in GDM compared to 
healthy pregnancy in second trimester (73). Fatty 
acid-binding protein 4 (FABP-4) is a protein highly 
expressed in adipocytes, and its concentrations in 
plasma are significantly increased in obese sub-
jects and those with GDM compared to healthy 
pregnant women in second trimester according to 
one small clinical study (74).
Extracellular vesicles (EVs), namely exosomes sized 
50-100 nm in diameter, are small vesicles released 
into the extracellular space with the ability to reach 
the blood circulation. EVs can be isolated from vari-
ous biological fluids (plasma, urine, and saliva) us-
ing chromatography or ultracentrifugation-free 
method, as performed by Arias et al. in the present-
ed clinical study and are very stable and able to pro-
tect their biological contents from degradation (75). 
They are involved in interorgan communication, 
and mediate the development and advancement 
of many disease states (76). It has been established 
that during physiological pregnancy, EV concentra-
tions are increased (especially exosomes of placen-
tal origin, found in maternal plasma). In women 
with GDM, EVs carry specific cargo. The characteri-
zation of the composition of EVs in GDM between 
gestational weeks 11 and 14 could be used for the 
identification of asymptomatic women who will de-
velop GDM, and their early treatment (77). The char-
acterization can be performed using flow cytome-
try, which is increasingly represented in routine clin-
ical laboratories.
Fetuin-A or α2-Heremans-Schmid glycoprotein 
(AHSG) is a 64 kDa glycoprotein that is produced 
by the liver and adipose tissue, and can be secret-
ed by the placenta during pregnancy (78,79). It can 
inhibit insulin signal transduction by disrupting in-
sulin receptor formation, which results in insulin 
resistance and the development of T2DM. Indeed, 
clinical studies have shown that increased plasma 
concentrations of fetuin-A and human obesity are 
strongly correlated with the onset of T2DM (80,81). 
Although several studies have yielded contradic-
tory findings concerning fetuin-A concentrations 
in GDM women, in other, fetuin-A was actually sig-
nificantly increased during the first and second tri-
mesters, and was associated with an increased risk 
of GDM development (80,82-84). Therefore, fetuin-
A is a good candidate biomarker for the risk of 
GDM. It is measured using ELISA method.
Recent studies, such as clinical study by Xu et al., 
have determined the connection between mater-
nal microbiota and pregnancy complications (85). 
Since the microbiome may also participate in the 
pathogenesis of several metabolic disorders, such 
as obesity, T2DM and GDM, the composition of 
the maternal oral or gut microbiota could be a 
predictive biomarker for GDM, namely, for the 
abundance of proinflammatory taxa (86,87). Char-
acterization of microbiota is being performed at 
the RNA level (by amplification and sequencing of 
the bacterial 16S rRNA gene) or DNA level (by 
whole genome sequencing). There are a number 
of obstacles to introducing both methods into 
clinical setting, such as cost of the equipment and 
training of clinicians to interpret the results (88). 
Additionally, since the composition of the microbi-
ome is determined by genotype and phenotype, 
https://doi.org/10.11613/BM.2021.030502 Biochem Med (Zagreb) 2021;31(3):030502 
  11
Omazić J. et al. Markers of gestational diabetes mellitus
and especially by diet, and since studies used dif-
ferent inclusion criteria (e.g., Crussell et al. selected 
participants that were overweight and those at 
high risk for GDM), the conclusions from studies 
on maternal microbiota are contradictory as re-
gards the utilization of the microbiome as a pre-
dictive GDM marker (89-91). Instead, microbiome 
composition may serve as a tool for monitoring 
maternal health, and for developing methods for 
the modulation of the gut microbiota in the name 
of maternal metabolic health (92).
In diabetes, the membrane glycoprotein CD59, 
which serves as a protective element against com-
plement-mediated lysis, is inactivated by non-en-
zymatic glycation and shed from the cell mem-
branes into the plasma. This plasma-glycated 
CD59 (pGCD59), measurable by flow cytometry, is 
used as a diabetes biomarker, and has recently 
been shown to be specific for GDM determination, 
even before the 20th week of gestation (93-95). 
Therefore, pGCD59 could become routine test for 
GDM and future studies will assess the exact point 
at which it should be measurable in plasma.
Previous review by Huhn et al. highlights placenta 
growth factor (PIGF) as a potential early marker of 
GDM alone and in combination with plasma pro-
tein-A (PAPP-A), but it also showed contradictory 
results (96). A more recent study involving PIGF is 
by Gorkem et al. and, although it included 158 
pregnant women and showed elevated serum 
PIGF values in pregnant women with GDM, study 
was done between 24 and 28 week of gestation 
and does not provide information whether PIGF is 
reliable early marker (97). Recently published small 
clinical study by Nuzzo et al. showed no difference 
between PIGF, soluble fms-like tyrosine kinase 1 
(sFlt1) and sFlt1/PIGF ratio between GDM pregnant 
women and healthy ones (98). 
Most often, these new biomarkers have been iden-
tified in single study, so it is difficult to comment on 
whether they are indeed a good early GDM bio-
marker. Additional research is needed for each indi-
vidual biomarker and the determination of exact 
cut-off value that would separate healthy pregnant 
women and women with GDM, at the earliest pos-
sible stage of pregnancy. Positive side is that major-
ity of new biomarkers are determined by immuno-
chemical ELISA method and are suitable for routine 
measurement in clinical laboratories although there 
is no reference method or sample for any of them, 
and the immunochemical methods are not compa-
rable. Therefore, special importance should be giv-
en to the interpretation of the obtained values, and 
this is an aggravating circumstance when determin-
ing cut-off values or reference intervals. 
Conclusion
Gestational diabetes mellitus is an increasingly 
common global health problem, and its early di-
agnosis remains a challenge since none of the ex-
isting biomarkers show high specificity for GDM 
and therefore, the diagnosis is made in the second 
trimester. Early diagnosis and treatment are crucial 
because inadequate intrauterine conditions for 
growth and development in the critical period of 
foetal life have an impact on foetal programing, 
and can induce disease in the early postnatal peri-
od as well as chronic disease later in life.
Our literature search for the new early biomarker 
of GDM resulted with few possible candidates: 
afamin, angiopoietin-like protein 8, characteriza-
tion of the composition of EVs, fetuin-A, FGF21, 
pGCD59. Each of them has increased or altered 
concentrations in early stages (mainly first trimes-
ter) of GDM pregnancies compared to healthy 
pregnancies and they are measurable in plasma or 
serum using laboratory techniques, which could 
be at some point automated. Future, more exten-
sive, studies are needed to measure and calculate 
their decision threshold and to evaluate their clini-
cal usefulness, availability of a referent method 
and referent material as well as analytical sensitivi-
ty and specificity of the methods used. 
Acknowledgments
Preparation of this manuscript was supported by 
Medical faculty Osijek institutional scientific projects: 
IP16-2020-Specificities of immunological profile in 
gestational diabetes and IP05-2019-Postpartal 
changes of metabolic profile in gestational diabetes.
Potential conflict of interest
None declared.
Biochem Med (Zagreb) 2021;31(3):030502  https://doi.org/10.11613/BM.2021.030502 
12
Omazić J. et al. Markers of gestational diabetes mellitus
References
1. Chorell E, Hall UA, Gustavsson C, Berntorp K, Puhkala J, 
Luoto R, et al. Pregnancy to postpartum transition of se-
rum metabolites in women with gestational diabetes. Me-
tabolism. 2017;72:27-36. https://doi.org/10.1016/j.meta-
bol.2016.12.018
2. Brink HS, van der Lely AJ, van der Linden J. The potential role 
of biomarkers in predicting gestational diabetes. Endocr 
Connect. 2016;5:R26–34. https://doi.org/10.1530/EC-16-0033
3. Simmons D, ed. Epidemiology of Diabetes in Pregnancy. In: 
McCance DR, Maresh M, Sacks DA, eds. A Practical Manual 
of Diabetes in Pregnancy. Chichester, UK: John Wiley & Sons; 
2017. p. 1-16. https://doi.org/10.1002/9781119043805.ch1
4. Lorenzo-Almorós A, Hang T, Peiró C, Soriano-Guillén L, Egi-
do J, Tuñón J, et al. Predictive and diagnostic biomarkers for 
gestational diabetes and its associated metabolic and car-
diovascular diseases. Cardiovasc Diabetol. 2019;18:140. 
https://doi.org/10.1186/s12933-019-0935-9
5. Kennelly MA, McAuliffe FM. Prediction and prevention of 
Gestational Diabetes: an update of recent literature. Eur 
J Obstet Gynecol Reprod Biol. 2016;202:92-8. https://doi.
org/10.1016/j.ejogrb.2016.03.032
6. Kopylov AT, Papysheva O, Gribova I, Kotaysch G, Kharito-
nova L, Mayatskaya T, et al. Molecular pathophysiology of 
diabetes mellitus during pregnancy with antenatal com-
plications. Sci Rep. 2020;10:19641. https://doi.org/10.1038/
s41598-020-76689-9
7. Rodrigo N, Glastras S. The Emerging Role of Biomarkers in 
the Diagnosis of Gestational Diabetes Mellitus. J Clin Med. 
2018;7:120. https://doi.org/10.3390/jcm7060120
8. Kebapcilar L. Is the Mean Platelet Volume a Predictive Mar-
ker of a Low Apgar Score and Insulin Resistance in Gestatio-
nal Diabetes Mellitus? A Retrospective Case-Control Study. 
J Clin Diagn Res. 2016;10:C06–10. https://doi.org/10.7860/
JCDR/2016/20874.8611
9. Pons RS, Rockett FC, de Almeida Rubin B, Oppermann MLR, 
Bosa VL. Risk factors for gestational diabetes mellitus in 
a sample of pregnant women diagnosed with the disea-
se. Diabetol Metab Syndr. 2015;7(Suppl 1):A80. https://doi.
org/10.1186/1758-5996-7-S1-A80
10. Basu J, Datta C, Chowdhury S, Mandal D, Mondal NK, Gho-
sh A. Gestational Diabetes Mellitus in a Tertiary Care Hos-
pital of Kolkata, India: Prevalence, Pathogenesis and Po-
tential Disease Biomarkers. Exp Clin Endocrinol Diabetes. 
2020;128:216-23. https://doi.org/10.1055/a-0794-6057
11. Djelti F, Merzouk H, Merzouk SA, Narce M. In vitro effects of 
oil’s fatty acids on T cell function in gestational diabetic pre-
gnant women and their newborns. J Diabetes. 2015;7:512-
22. https://doi.org/10.1111/1753-0407.12210
12. Wang J, Zhu Q-W, Cheng X-Y, Sha C-X, Cui Y-B. Clinical si-
gnificance of neutrophil–lymphocyte ratio and monocyte–
lymphocyte ratio in women with hyperglycemia. Postgrad 
Med. 2020;132:702-8. https://doi.org/10.1080/00325481.20
20.1764235
13. Kwon EJ, Kim YJ. What is fetal programming?: a lifetime he-
alth is under the control of in utero health. Obstet Gynecol 
Sci. 2017;60:506. https://doi.org/10.5468/ogs.2017.60.6.506
14. Andersson-Hall U, Carlsson N-G, Sandberg A-S, Holmäng 
A. Circulating Linoleic Acid is Associated with Improved 
Glucose Tolerance in Women after Gestational Diabe-
tes. Nutrients. 2018;10:1629-46. https://doi.org/10.3390/
nu10111629
15. Coustan DR, Lowe LP, Metzger BE, Dyer AR. The Hyperglyce-
mia and Adverse Pregnancy Outcome (HAPO) study: paving 
the way for new diagnostic criteria for gestational diabetes 
mellitus. Am J Obstet Gynecol. 2010;202:654.e1-e6. https://
doi.org/10.1016/j.ajog.2010.04.006
16. Diagnostic criteria and classification of hyperglycaemia first 
detected in pregnancy: a World Health Organization Guide-
line. Diabetes Res Clin Pract. 2014 Mar;103:341-63.
17. Croatian chamber of medical biochemists. [Laboratorij-
ska dijagnostika šećerne bolesti u trudnoći. Standardni la-
boratorijski postupak]. Available at: https://www.hkmb.hr/
dokumenti/2014/HKMB%20PPSP%203%20ispravak%20
JM%2021_02_14.pdf. Accessed March 29th 2021. (In Croa-
tian)
18. Huynh J, Xiong G, Bentley-Lewis R. A systematic review of 
metabolite profiling in gestational diabetes mellitus. Diabe-
tologia. 2014;57:2453-64. https://doi.org/10.1007/s00125-
014-3371-0
19. Vandorsten JP, Dodson WC, Espeland MA, Grobman WA, 
Guise JM, Mercer BM, et al. NIH consensus development con-
ference: diagnosing gestational diabetes mellitus. NIH Con-
sensus and State-of-the-science Statements. 2013;29:1-31. 
20. Agarwal MM, Hughes PF, Punnose J, Ezimokhai M, Tho-
mas L. Gestational diabetes screening of a multiethnic, 
high-risk population using glycated proteins. Diabetes Res 
Clin Pract. 2001;51:67-73. https://doi.org/10.1016/S0168-
8227(00)00206-0
21. Agarwal MM, Dhatt GS, Punnose J, Koster G. Gestatio-
nal diabetes: a reappraisal of HBA1c as a screening test. 
Acta Obstet Gynecol Scand. 2005;84:1159-63. https://doi.
org/10.1111/j.0001-6349.2005.00650.x
22. Rajput R, Yogesh Yadav  null, Rajput M, Nanda S. Utility of 
HbA1c for diagnosis of gestational diabetes mellitus. Diabe-
tes Res Clin Pract. 2012;98:104-7. https://doi.org/10.1016/j.
diabres.2012.02.018
23. Uncu G, Ozan H, Cengiz C. The comparison of 50 grams 
glucose challenge test, HbA1c and fructosamine levels in 
diagnosis of gestational diabetes mellitus. Clin Exp Obstet 
Gynecol. 1995;22:230-4. 
24. Lapolla A, Metzger BE, eds. Gestational Diabetes. A Decade 
after the HAPO Study. Front Diabetes. Basel, Karger, 2020, 
vol 28, pp I–VI. https://doi.org/10.1159/isbn.978-3-318-
06612-8
25. Fahami F, Torabi S, Abdoli S. Prediction of glucose intoleran-
ce at 24-28 weeks of gestation by glucose and insulin level 
measurements in the first trimester. Iran J Nurs Midwifery 
Res. 2015;20:81-6. 
26. Riskin-Mashiah S, Damti A, Younes G, Auslender R. First tri-
mester fasting hyperglycemia as a predictor for the deve-
lopment of gestational diabetes mellitus. Eur J Obstet Gyne-
col Reprod Biol. 2010;152:163-7. https://doi.org/10.1016/j.
ejogrb.2010.05.036
https://doi.org/10.11613/BM.2021.030502 Biochem Med (Zagreb) 2021;31(3):030502 
  13
Omazić J. et al. Markers of gestational diabetes mellitus
27. Donovan L, Hartling L, Muise M, Guthrie A, Vandermeer 
B, Dryden DM. Screening Tests for Gestational Diabe-
tes: A Systematic Review for the U.S. Preventive Services 
Task Force. Ann Intern Med. 2013;159:115-22. https://doi.
org/10.7326/0003-4819-159-2-201307160-00657
28. Li P, Lin S, Li L, Cui J, Zhou S, Fan J. First-trimester fasting pla-
sma glucose as a predictor of gestational diabetes melli-
tus and the association with adverse pregnancy outcomes. 
Pak J Med Sci. 2019;35:95-100. https://doi.org/10.12669/
pjms.35.1.216
29. Falcone V, Kotzaeridi G, Breil MH, Rosicky I, Stopp T, Yerli-
kaya-Schatten G, et al. Early Assessment of the Risk for Ge-
stational Diabetes Mellitus: Can Fasting Parameters of 
Glucose Metabolism Contribute to Risk Prediction? Dia-
betes Metab J. 2019;43:785-93. https://doi.org/10.4093/
dmj.2018.0218
30. Clark CM, Qiu C, Amerman B, Porter B, Fineberg N, Alda-
souqi S, et al. Gestational diabetes: should it be added to the 
syndrome of insulin resistance? Diabetes Care. 1997;20:867-
71. https://doi.org/10.2337/diacare.20.5.867
31. Correa PJ, Vargas JF, Sen S, Illanes SE. Prediction of Gesta-
tional Diabetes Early in Pregnancy: Targeting the Long-
Term Complications. Gynecol Obstet Invest. 2014;77:145-9. 
https://doi.org/10.1159/000357616
32. Bonakdaran S. Increased Serum Level of FGF21 in Ge-
stational Diabetes Mellitus. Acta Endocrinol (Buchar). 
2017;13:278-81. https://doi.org/10.4183/aeb.2017.278
33. Berggren EK, Boggess KA, Mathew L, Culhane J. First Trime-
ster Maternal Glycated Hemoglobin and Sex Hormone–Bin-
ding Globulin Do Not Predict Third Trimester Glucose Intole-
rance of Pregnancy. Reprod Sci. 2017;24:613-8. https://doi.
org/10.1177/1933719116667230
34. Faal S, Abedi P, Jahanfar S, Ndeke JM, Mohaghegh Z, Sha-
rifipour F, et al. Sex hormone binding globulin for pre-
diction of gestational diabetes mellitus in pre-concep-
tion and pregnancy: A systematic review. Diabetes Res 
Clin Pract. 2019;152:39-52. https://doi.org/10.1016/j.dia-
bres.2019.04.028
35. Bozkurt L, Göbl CS, Baumgartner-Parzer S, Luger A, Paci-
ni G, Kautzky-Willer A. Adiponectin and Leptin at Early Pre-
gnancy: Association to Actual Glucose Disposal and Risk 
for GDM - A Prospective Cohort Study. Int J Endocrinol. 
2018;2018:5463762. https://doi.org/10.1155/2018/5463762
36. Enquobahrie DA, Denis M, Tadesse MG, Gelaye B, Ressom 
HW, Williams MA. Maternal Early Pregnancy Serum Meta-
bolites and Risk of Gestational Diabetes Mellitus. J Clin En-
docrinol Metab. 2015;100:4348-56. https://doi.org/10.1210/
jc.2015-2862
37. Bentley-Lewis R, Huynh J, Xiong G, Lee H, Wenger J, Clish C, 
et al. Metabolomic profiling in the prediction of gestational 
diabetes mellitus. Diabetologia. 2015;58:1329-32. https://
doi.org/10.1007/s00125-015-3553-4
38. Mokkala K, Vahlberg T, Pellonperä O, Houttu N, Koivuniemi 
E, Laitinen K. Distinct Metabolic Profile in Early Pregnancy 
of Overweight and Obese Women Developing Gestational 
Diabetes. J Nutr. 2020;150:31-7. https://doi.org/10.1093/jn/
nxz220
39. White SL, Pasupathy D, Sattar N, Nelson SM, Lawlor DA, 
Briley AL, et al. Metabolic profiling of gestational diabe-
tes in obese women during pregnancy. Diabetologia. 
2017;60:1903-12. https://doi.org/10.1007/s00125-017-
4380-6
40. Burzynska-Pedziwiatr I, Jankowski A, Kowalski K, Sendys P, 
Zieleniak A, Cypryk K, et al. Associations of Arginine with 
Gestational Diabetes Mellitus in a Follow-Up Study. Int J Mol 
Sci. 2020;21:7811. https://doi.org/10.3390/ijms21217811
41. Pappa KI, Vlachos G, Theodora M, Roubelaki M, Angeli-
dou K, Antsaklis A. Intermediate metabolism in associa-
tion with the amino acid profile during the third trimester 
of normal pregnancy and diet-controlled gestational dia-
betes. Am J Obstet Gynecol. 2007;196:65.e1-e5. https://doi.
org/10.1016/j.ajog.2006.06.094
42. Nevalainen J, Sairanen M, Appelblom H, Gissler M, Timonen 
S, Ryynänen M. First-Trimester Maternal Serum Amino Acids 
and Acylcarnitines Are Significant Predictors of Gestatio-
nal Diabetes. Rev Diabet Stud. 2016;13:236-45. https://doi.
org/10.1900/RDS.2016.13.236
43. Rahimi N, Razi F, Nasli-Esfahani E, Qorbani M, Shirzad N, 
Larijani B. Amino acid profiling in the gestational diabetes 
mellitus. J Diabetes Metab Disord. 2017;16:13. https://doi.
org/10.1186/s40200-016-0283-1
44. Leitner M, Fragner L, Danner S, Holeschofsky N, Leitner K, 
Tischler S, et al. Combined Metabolomic Analysis of Pla-
sma and Urine Reveals AHBA, Tryptophan and Serotonin 
Metabolism as Potential Risk Factors in Gestational Diabe-
tes Mellitus (GDM). Front Mol Biosci. 2017;4:84. https://doi.
org/10.3389/fmolb.2017.00084
45. Law KP, Han T-L, Mao X, Zhang H. Tryptophan and puri-
ne metabolites are consistently upregulated in the urinary 
metabolome of patients diagnosed with gestational dia-
betes mellitus throughout pregnancy: A longitudinal me-
tabolomics study of Chinese pregnant women part 2. Clin 
Chim Acta. 2017;468:126-39. https://doi.org/10.1016/j.
cca.2017.02.018
46. Manta-Vogli PD, Schulpis KH, Dotsikas Y, Loukas YL. The si-
gnificant role of carnitine and fatty acids during pregnancy, 
lactation and perinatal period. Nutritional support in speci-
fic groups of pregnant women. Clin Nutr. 2020;39:2337-46. 
https://doi.org/10.1016/j.clnu.2019.10.025
47. Chavan-Gautam P, Rani A, Freeman DJ, eds. Distribution 
of Fatty Acids and Lipids During Pregnancy. In: Advances 
in Clinical Chemistry. Elsevier; 2018. p. 209-39. https://doi.
org/10.1016/bs.acc.2017.12.006
48. Meyer B, Calvert D, Moses R. Free fatty acids and gestational 
diabetes mellitus. Aust N Z J Obstet Gynaecol. 1996;36:255-
7. https://doi.org/10.1111/j.1479-828X.1996.tb02705.x
49. Lekva T, Norwitz ER, Aukrust P, Ueland T. Impact of Syste-
mic Inflammation on the Progression of Gestational Dia-
betes Mellitus. Curr Diab Rep. 2016;16:26. https://doi.
org/10.1007/s11892-016-0715-9
50. Amirian A, Rahnemaei FA, Abdi F. Role of C-reacti-
ve Protein(CRP) or high-sensitivity CRP in predicting ge-
stational diabetes Mellitus:Systematic review. Diabe-
tes Metab Syndr Clin Res Rev. 2020;14:229-36. https://doi.
org/10.1016/j.dsx.2020.02.004
Biochem Med (Zagreb) 2021;31(3):030502  https://doi.org/10.11613/BM.2021.030502 
14
Omazić J. et al. Markers of gestational diabetes mellitus
51. Powe CE. Early Pregnancy Biochemical Predictors of Gesta-
tional Diabetes Mellitus. Curr Diab Rep. 2017;17:12. https://
doi.org/10.1007/s11892-017-0834-y
52. Atègbo J-M, Grissa O, Yessoufou A, Hichami A, Dramane KL, 
Moutairou K, et al. Modulation of adipokines and cytokines 
in gestational diabetes and macrosomia. J Clin Endocrinol 
Metab. 2006;91:4137-43. https://doi.org/10.1210/jc.2006-
0980
53. Hichami A, Grissa O, Mrizak I, Benammar C, Khan NA. Role 
of T-Cell Polarization and Inflammation and Their Modu-
lation by n-3 Fatty Acids in Gestational Diabetes and Ma-
crosomia. J Nutr Metab. 2016;2016:3124960. https://doi.
org/10.1155/2016/3124960
54. Abell SK, De Courten B, Boyle J, Teede H. Inflammatory 
and Other Biomarkers: Role in Pathophysiology and Pre-
diction of Gestational Diabetes Mellitus. Int J Mol Sci. 
2015;16:13442-73. https://doi.org/10.3390/ijms160613442
55. Bergmann K, Sypniewska G. Diabetes as a complication of 
adipose tissue dysfunction. Is there a role for potential new 
biomarkers? Clin Chem Lab Med. 2013,51:177-85. https://
doi.org/10.1515/cclm-2012-0490
56. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, 
Yudkin JS, et al. Subcutaneous Adipose Tissue Releases In-
terleukin-6, But Not Tumor Necrosis Factor-α, in Vivo 1. 
J Clin Endocrinol Metab. 1997;82:4196-200. https://doi.
org/10.1210/jc.82.12.4196
57. Park HS, Park JY, Yu R. Relationship of obesity and visce-
ral adiposity with serum concentrations of CRP, TNF-α and 
IL-6. Diabetes Res Clin Pract. 2005;69:29-35. https://doi.
org/10.1016/j.diabres.2004.11.007
58. Khambule L, George JA. The Role of Inflammation in the De-
velopment of GDM and the Use of Markers of Inflammation 
in GDM Screening. In: Guest PC, editor. Reviews on Biomar-
ker Studies of Metabolic and Metabolism-Related Disorders. 
Cham: Springer International Publishing; 2019. p. 217-42. 
https://doi.org/10.1007/978-3-030-12668-1_12
59. Yang H, Zhu C, Ma Q, Long Y, Cheng Z. Variations of blood 
cells in prediction of gestational diabetes mellitus. J Perinat 
Med. 2015;43: 89-93.
60. Liu W, Lou X, Zhang Z, Chai Y, Yu Q. Association of neutrophil 
to lymphocyte ratio, platelet to lymphocyte ratio, mean pla-
telet volume with the risk of gestational diabetes mellitus. 
Gynecol Endocrinol. 2021;37:105-7. https://doi.org/10.1080
/09513590.2020.1780579
61. Sahbaz A, Cicekler H, Aynioglu O, Isik H, Ozmen U. Compari-
son of the predictive value of plateletcrit with various other 
blood parameters in gestational diabetes development. J 
Obstet Gynaecol. 2016;36:589-93. https://doi.org/10.3109/0
1443615.2015.1110127
62. Sun T, Meng F, Zhao H, Yang M, Zhang R, Yu Z, et al. Ele-
vated First-Trimester Neutrophil Count Is Closely Associa-
ted With the Development of Maternal Gestational Diabe-
tes Mellitus and Adverse Pregnancy Outcomes. Diabetes. 
2020;69:1401–10. https://doi.org/10.2337/db19-0976
63. Fagundes DLG, França EL, Gonzatti MB, Rugde MVC, Calde-
ron IMP, Honorio-França AC. The modulatory role of cytoki-
nes IL-4 and IL-17 in the functional activity of phagocytes in 
diabetic pregnant women. APMIS. 2018;126:56-64. https://
doi.org/10.1111/apm.12772
64. Seck A, Hichami A, Doucouré S, Diallo Agne F, Bassène H, Ba 
A, et al. Th1/Th2 Dichotomy in Obese Women with Gestati-
onal Diabetes and Their Macrosomic Babies. J Diabetes Res. 
2018;2018:8474617. https://doi.org/10.1155/2018/8474617
65. Mahmoud F, Abul H, Omu A, Haines D. Lymphocyte sub-po-
pulations in gestational diabetes. Am J Reprod Immunol 
N Y N 1989. 2005;53:21-9. https://doi.org/10.1111/j.1600-
0897.2004.00241.x
66. Mahmoud FF, Haines DD, Abul HT, Omu AE, Abu-Donia 
MB. Butyrylcholinesterase Activity in Gestational Diabetes: 
Correlation with Lymphocyte Subpopulations in Peripheral 
Blood. Am J Reprod Immunol. 2006;56:185-92. https://doi.
org/10.1111/j.1600-0897.2006.00416.x
67. Pendeloski KPT, Mattar R, Torloni MR, Gomes CP, Alexandre 
SM, Daher S. Immunoregulatory molecules in patients with 
gestational diabetes mellitus. Endocrine. 2015;50:99-109. 
https://doi.org/10.1007/s12020-015-0567-0
68. Köninger A, Mathan A, Mach P, Frank M, Schmidt B, Schle-
ussner E, et al. Is Afamin a novel biomarker for gestatio-
nal diabetes mellitus? A pilot study. Reprod Biol Endocrinol. 
2018;16:30-41. https://doi.org/10.1186/s12958-018-0338-x
69. Zibar K, Blaslov K, Bulum T, Ćuća JK, Smirčić-Duvnjak L. Ba-
sal and postprandial change in serum fibroblast growth 
factor-21 concentration in type 1 diabetic mellitus and in 
healthy controls. Endocrine. 2015;48:848-55. https://doi.
org/10.1007/s12020-014-0413-9
70. Huang Y, Chen X, Chen X, Feng Y, Guo H, Li S, et al. Angiopoi-
etin-like protein 8 in early pregnancy improves the predic-
tion of gestational diabetes. Diabetologia. 2018;61:574-80. 
https://doi.org/10.1007/s00125-017-4505-y
71. Sibiak R, Jankowski M, Gutaj P, Mozdziak P, Kempisty B, 
Wender-Ożegowska E. Placental Lactogen as a Marker of 
Maternal Obesity, Diabetes, and Fetal Growth Abnormaliti-
es: Current Knowledge and Clinical Perspectives. J Clin Med. 
2020;9:1142-61. https://doi.org/10.3390/jcm9041142
72. Zhang Z, Gu C, Fang P, Shi M, Wang Y, Peng Y, et al. Endo-
genous galanin as a novel biomarker to predict gestatio-
nal diabetes mellitus. Peptides. 2014;54:186-9. https://doi.
org/10.1016/j.peptides.2014.01.024
73. Dincgez Cakmak B, Dundar B, Ketenci Gencer F, Yildiz DE, 
Bayram F, Ozgen G, et al. Assessment of relationship betwe-
en serum vascular adhesion protein-1 (VAP-1) and gestati-
onal diabetes mellitus. Biomarkers. 2019;24:750-6. https://
doi.org/10.1080/1354750X.2019.1684562
74. Ning H, Tao H, Weng Z, Zhao X. Plasma fatty acid-binding 
protein 4 (FABP4) as a novel biomarker to predict gestatio-
nal diabetes mellitus. Acta Diabetol. 2016;53:891-8. https://
doi.org/10.1007/s00592-016-0867-8
75. Arias M, Monteiro LJ, Acuña-Gallardo S, Varas-Godoy M, 
Rice GE, Monckeberg M, et al. Vesículas extracelulares como 
predictores tempranos de diabetes gestacional. Rev Médi-
ca Chile. 2019;147:1503-9. https://doi.org/10.4067/S0034-
98872019001201503
76. Jayabalan N, Lai A, Ormazabal V, Adam S, Guanzon D, Pal-
ma C, et al. Adipose Tissue Exosomal Proteomic Profile Re-
veals a Role on Placenta Glucose Metabolism in Gestational 
https://doi.org/10.11613/BM.2021.030502 Biochem Med (Zagreb) 2021;31(3):030502 
  15
Omazić J. et al. Markers of gestational diabetes mellitus
Diabetes Mellitus. J Clin Endocrinol Metab. 2019;104:1735-
52. https://doi.org/10.1210/jc.2018-01599
77. Buca D, Bologna G, D’Amico A, Cugini S, Musca F, Febbo M, 
et al. Extracellular Vesicles in Feto–Maternal Crosstalk and 
Pregnancy Disorders. Int J Mol Sci. 2020;21:2120-37. https://
doi.org/10.3390/ijms21062120
78. Trepanowski JF, Mey J, Varady KA. Fetuin-A: a novel link 
between obesity and related complications. Int J Obes (Lond). 
2015;39:734-41. https://doi.org/10.1038/ijo.2014.203
79. Pedersen KO. Fetuin, a New Globulin Isolated from Serum. 
Nature. 1944;154:575. https://doi.org/10.1038/154575a0
80. Jin C, Lin L, Han N, Zhao Z, Liu Z, Luo S, et al. Effects of 
dynamic change in fetuin-A levels from the first to the se-
cond trimester on insulin resistance and gestational diabe-
tes mellitus: a nested case–control study. BMJ Open Diabe-
tes Res Care. 2020;8:e000802. https://doi.org/10.1136/bmj-
drc-2019-000802
81. Lu D, Yang M, Yao Y, Xie Y. A clinical research study on the 
respective relationships between visfatin and human fetu-
in A and pregnancy outcomes in gestational diabetes melli-
tus. Taiwan J Obstet Gynecol. 2019;58:808-13. https://doi.
org/10.1016/j.tjog.2019.09.015
82. Kansu-Celik H, Ozgu-Erdinc AS, Kisa B, Findik RB, Yilmaz C, 
Tasci Y. Prediction of gestational diabetes mellitus in the 
first trimester: comparison of maternal fetuin-A, N-ter-
minal proatrial natriuretic peptide, high-sensitivity C-re-
active protein, and fasting glucose levels. Arch Endocri-
nol Metab. 2019;63:121-7. https://doi.org/10.20945/2359-
3997000000126
83. Schiavone M, Putoto G, Laterza F, Pizzol D. Gestational dia-
betes: An overview with attention for developing countries. 
Endocr Regul. 2016;50:62-71. https://doi.org/10.1515/enr-
2016-0010
84. Świrska J, Zwolak A, Dudzińska M, Matyjaszek-Matuszek B, 
Paszkowski T. Gestational diabetes mellitus - literature re-
view on selected cytokines and hormones of confirmed or 
possible role in its pathogenesis. Ginekol Pol. 2018;89:522-7. 
https://doi.org/10.5603/GP.a2018.0089
85. Xu Y, Zhang M, Zhang J, Sun Z, Ran L, Ban Y, et al. Differen-
tial intestinal and oral microbiota features associated with 
gestational diabetes and maternal inflammation. Am J 
Physiol-Endocrinol Metab. 2020;319:E247-53. https://doi.
org/10.1152/ajpendo.00266.2019
86. Zhang D, Huang Y, Ye D. Intestinal dysbiosis: An emer-
ging cause of pregnancy complications? Med Hypotheses. 
2015;84:223-6. https://doi.org/10.1016/j.mehy.2014.12.029
87. Cani PD, Geurts L, Matamoros S, Plovier H, Duparc T. Gluco-
se metabolism: Focus on gut microbiota, the endocannabi-
noid system and beyond. Diabetes Metab. 2014;40:246-57. 
https://doi.org/10.1016/j.diabet.2014.02.004
88. McIntyre HD, Kapur A, Divakar H, Hod M. Gestational diabe-
tes mellitus-Innovative approach to prediction, diagnosis, 
management, and prevention of future NCD-Mother and 
offspring. Front Endocrinol (Lausanne). 2020;11:614533. 
https://doi.org/10.3389/fendo.2020.614533
89. Cotillard A, Kennedy SP, Kong LC, Prifti E, Pons N, Le Chatelier 
E, et al. Dietary intervention impact on gut microbial gene 
richness. Nature. 2013;500:585-8. https://doi.org/10.1038/
nature12480
90. Crusell MKW, Hansen TH, Nielsen T, Allin KH, Rühlemann 
MC, Damm P, et al. Gestational diabetes is associated with 
change in the gut microbiota composition in third trime-
ster of pregnancy and postpartum. Microbiome. 2018;6:89. 
https://doi.org/10.1186/s40168-018-0472-x
91. Cortez RV, Taddei CR, Sparvoli LG, Ângelo AGS, Padilha 
M, Mattar R, et al. Microbiome and its relation to gesta-
tional diabetes. Endocrine. 2019;64:254-64. https://doi.
org/10.1007/s12020-018-1813-z
92. Ferrocino I, Ponzo V, Gambino R, Zarovska A, Leone F, Mon-
zeglio C, et al. Changes in the gut microbiota composi-
tion during pregnancy in patients with gestational dia-
betes mellitus (GDM). Sci Rep. 2018;8:12216. https://doi.
org/10.1038/s41598-018-30735-9
93. Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, 
Waldmann H, et al. Human protectin (CD59), an 18,000-
20,000 MW complement lysis restricting factor, inhibits C5b-
8 catalysed insertion of C9 into lipid bilayers. Immunology. 
1990;71:1-9.  
94. Ghosh P, Vaidya A, Sahoo R, Goldfine A, Herring N, Bry L, et 
al. Glycation of the Complement Regulatory Protein CD59 
Is a Novel Biomarker for Glucose Handling in Humans. J 
Clin Endocrinol Metab. 2014;99:E999-1006. https://doi.
org/10.1210/jc.2013-4232
95. Ma D, Luque-Fernandez MA, Bogdanet D, Desoye G, Dunne 
F, Halperin JA. Plasma Glycated CD59 Predicts Early Gesta-
tional Diabetes and Large for Gestational Age Newborns. 
J Clin Endocrinol Metab. 2020;105:e1033-40. https://doi.
org/10.1210/clinem/dgaa087
96. Huhn EA, Rossi SW, Hoesli I, Gobl CS. Controversies in scree-
ning and diagnostic criteria for GDM in early and late pre-
gnancy. Front Endocrinol (Lausanne). 2018;9:696. https://
doi.org/10.3389/fendo.2018.00696
97. Gorkem U, Togrul C, Arslan E. Relationship between eleva-
ted serum level of placental growth factor and status of ge-
stational diabetes mellitus. J Matern Fetal Neonatal Med. 
2020;33:4159-63. https://doi.org/10.1080/14767058.2019.1
598361
98. Nuzzo AM, Giuffrida D, Moretti L, Re P, Grassi G, Menato G, 
Rolfo A. Placental and maternal sFlt1/PIGF expression in ge-
stational diabetes mellitus. Sci Rep. 2021;11:2312. https://
doi.org/10.1038/s41598-021-81785-5
